Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927769 | 0.92 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6922587 | 0.85 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6927980 | 0.82 | HTR2C (0.57) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6930295 | 0.81 | SLC6A4 (0.44) | SLC6A4TDP1SLC6A2SLC6A3HTR1A | |
| SCHEMBL6922676 | 0.80 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL8634189 | 0.79 | SLC6A4 (0.56) | SLC6A4TDP1HTR1A | |
| SCHEMBL20524638 | 0.79 | TDP1 (0.50) | SLC6A4TDP1SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL29002479 | 0.78 | TDP1 (0.52) | SLC6A4TDP1SLC6A2HTR1A | |
| SCHEMBL1405196 | 0.76 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6928732 | 0.75 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | claimed |